Solasia Pharma KK (FRA:9SO) Change In Receivables: €1.92 Mil (TTM As of Jun. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Solasia Pharma KK FRA:9SO

70 GF Score

Price €0.14

GF Value €0.15

Valuation Fairly Valued

5 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Solasia Pharma KK Change In Receivables?

Solasia Pharma KK FRA:9SO 70 Change In Receivables is €1.92 Mil as of Jun. 2026. GuruFocus rates FRA:9SO with a GF Score™ of 70/100 and a GF Value™ of €0.15 (Fairly Valued). The stock has 5 warning signs investors should review.

Solasia Pharma KK's change in receivables for the quarter that ended in Jun. 2026 was €0.08 Mil. It means Solasia Pharma KK's Accounts Receivable declined by €0.08 Mil from Mar. 2026 to Jun. 2026 .

Solasia Pharma KK's change in receivables for the fiscal year that ended in Dec. 2025 was €0.00 Mil. It means Solasia Pharma KK's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Solasia Pharma KK's Accounts Receivable for the quarter that ended in Jun. 2026 was €0.12 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Solasia Pharma KK's Days Sales Outstanding for the three months ended in Jun. 2026 was 987.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Solasia Pharma KK's liquidation value for the three months ended in Jun. 2026 was €5.35 Mil.

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Solasia Pharma KK (FRA:9SO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Solasia Pharma KK's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.119	/	0.011	*	91
=	987.16

2. In Ben Graham's calculation of liquidation value, Solasia Pharma KK's accounts receivable are only considered to be worth 75% of book value:

Solasia Pharma KK's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.959	-	2.403	+	0.75 * 0.119	+	0.5 * 1.409
=	5.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solasia Pharma KK Change In Receivables Related Terms

Solasia Pharma KK Change In Receivables Historical Data

* Premium members only.

The historical data trend for Solasia Pharma KK's Change In Receivables can be seen below:

Solasia Pharma KK Change In Receivables Chart

Solasia Pharma KK Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Change In Receivables

Get a 7-Day Free Trial

0.40

-3.12

3.44

-1.02

0.00

Solasia Pharma KK Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
Change In Receivables	Get a 7-Day Free Trial															-0.02	0.00	0.00	1.84	0.08

70GF Score

Solasia Pharma KK FRA:9SO

Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Solasia Pharma KK Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.92 Mil.

Frequently Asked Questions Learn more about Change In Receivables →

What does a Change In Receivables of €1.92 Mil mean?

Solasia Pharma KK (FRA:9SO) has a Change In Receivables of €1.92 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Solasia Pharma KK and its competitors.

Is Solasia Pharma KK's Change In Receivables too high?

Solasia Pharma KK's current Change In Receivables is €1.92 Mil. Overall, Solasia Pharma KK has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Solasia Pharma KK's Change In Receivables compare to ZTS?

Solasia Pharma KK's Change In Receivables of €1.92 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Receivables for a Drug Manufacturers company?

A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Receivables mean?

A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Solasia Pharma KK and its competitors. Solasia Pharma KK's current Change In Receivables is €1.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Solasia Pharma KK stock overvalued right now?

Based on GuruFocus' analysis, Solasia Pharma KK (FRA:9SO) is currently considered Fairly Valued. The stock's GF Value™ is €0.15, compared to a current price of €0.14 — trading 8.7% below its estimated fair value. The current Change In Receivables is €1.92 Mil. Solasia Pharma KK's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Receivables calculated?

Change In Receivables is calculated from a company's financial statements. For Solasia Pharma KK (FRA:9SO), the current Change In Receivables is €1.92 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solasia Pharma KK (FRA:9SO) Overvalued in 2026?

Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be undervalued. The current stock price of €0.14 is trading 8.7% below its estimated GF Value™ of €0.15. GuruFocus considers Solasia Pharma KK to be Fairly Valued.

Key valuation signals for FRA:9SO:

Change In Receivables: €1.92 Mil
GF Value™: €0.15 vs. price of €0.14 (8.7% below fair value)
GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the FRA:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →